ANI Deferred Long Term Liab from 2010 to 2025
| ANIP Stock | USD 55.01 0.50 0.92% |
Deferred Long Term Liabilities | First Reported 2011-06-30 | Previous Quarter 600 K | Current Value 500 K | Quarterly Volatility 437.1 K |
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 72.2 M, Interest Expense of 32.5 M or Selling General Administrative of 181.6 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
ANI | Deferred Long Term Liab |
Latest ANI Pharmaceuticals' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of ANI Pharmaceuticals over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. ANI Pharmaceuticals' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
ANI Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 421,566 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 104.92 | |
| Mean Deviation | 368,870 | |
| Median | 500,000 | |
| Standard Deviation | 442,319 | |
| Sample Variance | 195.6B | |
| Range | 1.5M | |
| R-Value | 0.62 | |
| Mean Square Error | 129.8B | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | 57,323 | |
| Total Sum of Squares | 2.9T |
ANI Deferred Long Term Liab History
About ANI Pharmaceuticals Financial Statements
ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 690 K | 458.1 K |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.